Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2021 2020 2021 2020 Net Earnings, after tax- as reported $3,667 $3,554 $16,142 $12,976 Pre-tax Adjustments Intangible Asset Amortization expense 1,159 1,181 3,576 3,426 Litigation expense, net 2,077 1,477 2,054 2,210 IPR&D 900 138 900 144 Restructuring related 121 130 333 363 Acquisition, integration and divestiture related ยน 20 (154) (504) (1,087) (Gains)/losses on securities (127) 32 (335) (174) Medical Device Regulation 59 38 161 89 Other - 3 - 6 Tax Adjustments Tax impact on special item adjustments 2 (849) (482) (1,097) (1,002) Tax legislation and related impacts (59) (49) (713) (483) Adjusted Net Earnings, after tax $6,968 $5,868 $20,517 $16,468 Average shares outstanding (Diluted) 2,674.9 2,669.3 2,674.6 2,670.8 Adjusted net earnings per share (Diluted) $2.60 $2.20 $7.67 $6.17 Operational adjusted net earnings per share (Diluted) $2.56 $7.47 Notes: 1 2 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. Third Quarter Nine Months Ended Acquisition, integration and divestiture related for the nine months of 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S. Acquisition, integration and divestiture related for 2020 primarily includes a Contingent Consideration reversal ($165M in third quarter and $1,148M in nine months) related to the timing of certain developmental milestones associated with the Auris Health acquisition. -- 1 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical Medical Devices Total WW As Reported 5.3% 13.8% 8.0% 10.7% U.S. 4.5% 12.2% 0.8% 7.9% International 5.9% 15.9% 15.4% 13.8% WW Currency 1.2 0.6 1.0 0.8 U.S. - - - - International 2.2 1.3 2.1 1.7 WW Operational 4.1% 13.2% 7.0% 9.9% U.S. 4.5% 12.2% 0.8% 7.9% International 3.7% 14.6% 13.3% 12.1% General Surgery Advanced Sterilization Products 0.4 0.1 U.S. 0.0 0.0 International 0.8 0.2 Skin Health / Beauty Dr. Ci Labo - Sedona 1.1 0.2 U.S. 0.0 0.0 International 2.0 0.4 All Other Acquisitions and Divestitures 0.5 0.6 0.2 0.4 U.S. 0.6 0.0 0.3 0.1 International 0.3 1.4 0.0 0.8 WW Adjusted Operational 5.7% 13.8% 7.6% 10.6% U.S. 5.1% 12.2% 1.1% 8.0% International 6.1% 16.0% 14.1% 13.5% Adjusted Operational Sales Growth THIRD QUARTER 2021 ACTUAL vs. 2020 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 2 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical Medical Devices Total WW As Reported 5.2% 13.5% 23.4% 14.7% U.S. 2.8% 10.3% 20.6% 11.7% International 7.3% 17.5% 26.0% 18.0% WW Currency 2.1 2.2 2.9 2.3 U.S. - - - - International 3.8 5.0 5.5 4.9 WW Operational 3.1% 11.3% 20.5% 12.4% U.S. 2.8% 10.3% 20.6% 11.7% International 3.5% 12.5% 20.5% 13.1% General Surgery Advanced Sterilization Products 0.6 0.2 U.S. 0.0 0.0 International 1.2 0.3 Skin Health / Beauty Dr. Ci Labo - Sedona 0.5 0.1 U.S. 0.0 0.0 International 0.9 0.2 All Other Acquisitions and Divestitures 0.5 0.5 0.2 0.4 U.S. 0.5 (0.1) 0.4 0.1 International 0.3 1.3 0.0 0.7 WW Adjusted Operational 4.1% 11.8% 21.4% 13.1% U.S. 3.3% 10.2% 21.0% 11.8% International 4.7% 13.8% 21.7% 14.4% Note: Percentages are based on actual, non-rounded figures and may not sum Adjusted Operational Sales Growth NINE MONTHS 2021 ACTUAL vs. 2020 ACTUAL Segments -- 3 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2021 2020 2021 2020 2021 2020 2021 2020 2021 2020 Reported Income/(loss) Before Tax by Segment $ (636) 191 4,259 3,439 423 1,010 (197) (239) 3,849 4,401 % to Sales -17.2% 5.4% 32.8% 30.1% 6.4% 16.4% -0.8% -1.1% 16.5% 20.9% Intangible asset amortization expense 103 104 799 828 257 249 - - 1,159 1,181 In-process research and development - - - - 900 138 - - 900 138 Litigation related 1,359 531 756 971 (38) (25) - - 2,077 1,477 Loss/(gain) on securities 1 (1) (135) 31 7 2 - - (127) 32 Restructuring related 36 31 17 29 68 70 - - 121 130 Acquisition, integration and divestiture related - - 3 1 17 (155) - - 20 (154) Medical Device Regulation - - - - 59 38 - - 59 38 Other - - - - - 3 - - - 3 Adjusted Income Before Tax by Segment $ 863 856 5,699 5,299 1,693 1,330 (197) (239) 8,058 7,246 % to Sales 23.3% 24.4% 43.9% 46.4% 25.5% 21.6% -0.8% -1.1% 34.5% 34.4% *Estimated as of 10/19/2021. Q3 QTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Pharmaceutical Medical Devices Unallocated Worldwide Total -- 4 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2021 2020 2021 2020 2021 2020 2021 2020 2021 2020 Reported Income Before Tax by Segment $ 956 993 13,838 11,787 3,798 2,681 (652) (611) 17,940 14,850 % to Sales 8.7% 9.5% 36.6% 35.4% 18.8% 16.4% -0.9% -1.0% 26.0% 24.7% Intangible asset amortization expense 314 306 2,497 2,378 765 742 - - 3,576 3,426 In-process research and development - - - - 900 144 - - 900 144 Litigation related 1,481 1,169 675 1,006 (102) 35 - - 2,054 2,210 Loss/(gain) on securities (19) - (249) (177) (67) 3 - - (335) (174) Restructuring related 91 69 54 70 188 224 - - 333 363 Acquisition, integration and divestiture related - - (567) 20 63 (1,107) - - (504) (1,087) Medical Device Regulation - - - - 161 89 - - 161 89 Other - - - - - 6 - - - 6 Adjusted Income Before Tax by Segment $ 2,823 2,537 16,248 15,084 5,706 2,817 (652) (611) 24,125 19,827 % to Sales 25.7% 24.3% 43.0% 45.3% 28.2% 17.2% -0.9% -1.0% 35.0% 33.0% *Estimated as of 10/19/2021. Q3 YTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Pharmaceutical Medical Devices Unallocated Worldwide Total -- 5 of 6 -- Third Quarter Third Quarter Oct. 3, 2021 GAAP Intangible asset amortization Litigation expense, net Restructuring related Medical Device Regulation Other Oct. 3, 2021 Non-GAAP Cost of products sold 7,250 $ (1,133) (18) (22) 6,077 Selling, marketing and admin expenses 6,000 (6) 5,994 Research and development expense 3,422 - (31) 3,391 Other (Income) / Expense 1,850 (26) (2,077) (43) (20) 127 - (189) In-process research and development 900 (900) - Restructuring 60 (60) - Provision for taxes on income 182 165 433 202 22 (6) 22 11 59 - 1,090 Net Earnings 3,667 994 1,644 698 99 26 (149) 48 (59) - 6,968 Third Quarter Third Quarter Sept. 27, 2020 GAAP Intangible asset amortization Litigation expense, net Restructuring related Medical Device Regulation Other Sept. 27, 2020 Non-GAAP Cost of products sold 6,972 $ (1,181) (32) (18) 5,741 Selling, marketing and admin expenses 5,431 (4) 5,427 Research and development expense 2,840 5 (16) 2,829 Other (Income) / Expense 1,200 - (1,477) (30) 149 (32) (3) (193) In-process research and development 138 (138) - Restructuring 68 (68) - Provision for taxes on income 847 187 230 29 22 3 5 7 49 (1) 1,378 Net Earnings 3,554 994 1,247 109 108 (157) 27 31 (49) 4 5,868 Nine Months Nine Months Oct. 3, 2021 GAAP Intangible asset amortization Litigation expense, net Restructuring related Medical Device Regulation Other Oct. 3, 2021 Non-GAAP Cost of products sold 21,900 $ (3,550) (65) (59) 18,226 Selling, marketing and admin expenses 17,505 (17) 17,488 Research and development expense 9,994 - (85) 9,909 Other (Income) / Expense 480 (26) (2,054) - (99) 504 335 - (860) In-process research and development 900 (900) - - - Restructuring 169 (169) - Provision for taxes on income 1,798 505 432 202 59 (104) (27) 30 713 - 3,608 Net Earnings 16,142 3,071 1,622 698 274 (400) (308) 131 (713) - 20,517 Nine Months Nine Months Sept. 27, 2020 GAAP Intangible asset amortization Litigation expense, net Restructuring related Medical Device Regulation Other Sept. 27, 2020 Non-GAAP Cost of products sold 20,613 $ (3,426) (69) (40) 17,078 Selling, marketing and admin expenses 15,627 (10) 15,617 Research and development expense 8,127 - (39) 8,088 Other (Income) / Expense 545 - (2,210) (107) 1,087 174 (6) (517) In-process research and development 144 (144) - Restructuring 187 (187) - Provision for taxes on income 1,874 550 373 30 65 10 (42) 16 483 - 3,359 Net Earnings 12,976 2,876 1,837 114 298 (1,097) (132) 73 (483) 6 16,468 (1) 2021 primarily includes gains on the divestitures of two Pharmaceutical brands outside of the United States. 2020 primarily includes a Contingent Consideration reversal of $1,148M related to the timing of certain developmental milestones associated with the Auris Health acquisition. In-process research and development Acquisition, integration and divestiture related (1) (Loss)/Gain on securities Tax legislation and other tax related In-process research and development Acquisition, integration and divestiture related (Loss)/Gain on securities Tax legislation and other tax related Year to Date In-process research and development Acquisition, integration and divestiture related (1) (Loss)/Gain on securities Tax legislation and other tax related Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date In-process research and development Acquisition, integration and divestiture related (Loss)/Gain on securities Tax legislation and other tax related -- 6 of 6 --